

Healthcare. We Care.



Aspen is a **global supplier** of branded and generic **pharmaceutical products** 



Aspen products are provided in more than **150 countries** around the world. Products are divided in **3 therapeutic categories**: Thrombosis, anaesthetics, cytotoxics



18 manufacturing sites of pharmaceutical products on 6 continents (North and South America – Asia – Africa – Oceania – Europe)



More than 10 000 employees all around the world



# Manufacturing sites in Europe

# Aspen Oss, The Netherlands Acquired in 2013

Manufactures chemical and biochemical active pharmaceutical ingredients

Aspen Notre-Dame-de-Bondeville, France Acquired in 2014

Manufactures finished form prefilled syringes



### Aspen Bad Oldesloe, Germany

Acquired in 2009

Manufactures finished form tablets, creams, liquids and nebules





#### FRAXIPARINE TM / FRAXODI TM

Low molecular weight heparin indicated for venous thromboembolic events

100 millions d'unités



#### ARIXTRA TM

Unique synthetic injectable inhibitor of Factor Xa approved for a range of uses in VTE treatment/prophylaxis and treatment of acute coronary syndromes

35 millions d'unités



#### MONO EMBOLEX™

Low molecular weight heparin indicated for venous thromboembolic events

30 millions d'unités



#### **DILUANTS**

Production of diluents syringes for third part contractor, used for reconstitution of vaccines prior to injection or oral administration

15 millions d'unités






**91%** of production shipped internationally (105 countries)



**127** Million units shipped




# Our history





# A site of excellence for the Aspen Group



#### 

Main mission for the supply chain and production of Biochem ASPEN products :

- Provide technical support
- Define a common quality and regulatory approach
- Provide supervision from a performance and project management point of view

The Center of Excellence Biochem will focus on the active ingredients associated with ASPEN's portfolio of anticoagulant products :

Danaparoide sodium (Orgaran®)
Nadroparine calcium (Fraxiparine®/Fraxodi®)
Fondaparinux sodium (Arixtra®)


# CES Center of Excellence Sterile

- Mutualize key skills
- Actively participate in international conferences, seminars and forums (PDA, SFSTP, PIC, etc.)
- Harmonize practices (Quality, Regulation...)
- Develop skills / aptitudes for the future
- Assist sites and external partners in problem solving and technology choices
- Improve the sites and the supply chain performance





NDB PEOPLE









SITE MANAGEMENT Jean-Charles ROUSSET

Managing Director



QUALITY & RESPONSIBLE PHARMACIST Patrick ROUSSEAU

Director



LOGISTICS & PROCUREMENT Arnaud BEAUDOUIN

Director



TRANSFORMATION, HR & COMMUNICATION
Vincent Philibert

Director



API & FILLING VS Ingrid TOUZET

Director



TECHNICAL Didier SIMION

Director



FINANCE Rabah RAFA

Director



VISUAL INSPECTION & PACKAGING Simona VLASA

Director



S.H.E Luc PARENT


Director



LEGAL, ETHICS & COMPLIANCE Pauline Charles

Senior Manager









### Site employees engaged to support local associations





























OUR PRODUCTION EQUIPMENT



3 API manufacturing workshops



3 inspection lines



10 packaging lines

2 sterile filling lines







### API MANUFACTURING WORKSHOPS

#### Sodium Fondaparinux: Arixtra™API

Building U: production launched in September 2004

Purification steps of Fondaparinux

2 shifts 5 days operation

Production capacity: 36 batches of purified Fondaparinux per year





Nadroparin Calcium: Fraxiparine™ API

Launched in 1985

Refurbishment in 2011 - 2012 - 2016

Production capacity: 200 batches per year

1 shift 5 days operation

#### Sodium Certoparin: MonoEmbolex™ API

Launch of the first validation batches in 2017

Expected volume: 45 batches per year





### 2 high-speed filling lines:

**Etna line** : Fraxiparine™ + Arixtra™ + WFI + MonoEmbolex ™

**Stromboli line**: Fraxiparine™ + MonoEmbolex ™

- · Aseptic filling under isolator
- E-beam
- · Final sterilization by autoclaving









### 3 inspection lines:

- Etna line (automatic): Fraxiparine™ Arixtra™ Monoembolex™
- Line 24 Maewa (automatic): Fraxiparine™, Arixtra™ & diluants
- Line 20 (semi-automatic): Fraxiparine™ & Arixtra™





### **Fraxiparine**™

- L23 / L15: Labelling
- L5 / L4 / L14: assembling & packaging
- L 27: assembling, labelling and packaging

#### Arixtra™

- **L16**: assembling, labelling & packaging
- L17: assembling, labelling & packaging
- L22: semi-automatic packaging
- L25: packaging line dedicated to Japan

#### MonoEmbolex™

- L16: assembling, labelling & packaging
- L17: assembling, labelling & packaging









### QUALITY CONTROL LABORATORY

#### The new quality control laboratory has been launched in 2017:

• Size: 2500 m<sup>2</sup> sur 3 levels

#### **Quality control laboratory activities: from** sample receipt to analysis results

#### Step 1

Receipt and distribution of samples











#### Results:

- > Analytical review
- > Conformity assessment of components, materials, production environments and products
- > Edition of the certificate of analysis



#### Step 2

#### Analysis:

- > Physical Chemistry
- > Microbiology
- > Packaging items control




# WAREHOUSE

#### Warehouse

- Capacity = 7 000 pallets
- Controlled temperature 15-25° C
- Operation 3 shifts x 5 days
- Store and stock status are managed by SAP system

#### **Equipments**

- Class C room for sampling operations
- Cold room 2 8° C
- Weighing room for raw materials in a close laminar flow hood









OUR COMMITMENTS



# Quality commitment

- → It's a team of women and men who supports the manufacturing department.
  Their target is to put on the market safe, effective and quality medicines
- → 24 pharmacists work on site. 8 of them are entitled to batch release
- Quality missions are as follows:
  - Buildings and equipment
  - API and packaging components
  - Manufacturing
  - Packaging
  - Finished product control
  - Continuous improvement





# Health, Safety, Environment

Aspen NDB site has a Management System certified by DQS for OHSAS 18001, ISO 14001 and ISO 50001 standards


- → Based on continuous improvement, our SHE policy reflects the management's commitment into areas for progress such as:
  - Reduction of injuries
  - Improvement in Quality of WorkLife
  - Control of energy consumption and quantity of waste
  - Control of environmental aspects and risks of pollution
  - Compliance with our commitments to the authorities and the Aspen Group







# Environment performance



Invested for the environment since 2010



**76** % reduction from 2010 to 2017



waste buried since 2012

Reduction of **33** % from 2010 to 2017

**75**% of waste is recycled





2017